Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Annuloplasty System Promotes Mitral Valve Repair

By HospiMedica International staff writers
Posted on 29 Sep 2015
An implantable mitral reconstruction device proves a highly effective treatment option for reducing functional mitral regurgitation (MR).

The Cardioband mitral reconstruction system combines a reconstruction implant that is connected to the mitral annulus using specially designed anchors, and a transfemoral, transseptal delivery system. More...
The mitral annulus is reshaped under echocardiographic guidance for real-time adjustment on the beating heart, thus delivering optimal MR reduction results. The transcatheter, supra-annular approach does not interfere with the mitral valve leaflets or chordae, and does not preclude subsequent treatment options if they become necessary.

In a multicenter feasibility trial that included more than 50 patients, Cardioband was shown to significantly reduce annular size, with significant improvement in MR. After six months of follow-up, 82% of the patients were categorized in NYHA Class I-II, with significant improvement of Minnesota quality of life and six-minute walk test scores. The Cardioband mitral reconstruction system is a product of Valtech Cardio (Or Yehuda, Israel), and has received the CE marking of approval.

“Receipt of the CE Mark is the culmination of concerted and concentrated efforts by many individuals, and it is the result of productive collaboration with the medical community,” said Amir Gross, founder and CEO of Valtech. “We are confident that Cardioband will prove to be a meaningful addition to physician's available treatment options in addressing MR, providing a first-line mitral valve repair option that preserves the ability to perform future percutaneous or surgical valve repair and replacement.”

“The future of functional mitral regurgitation treatment lies in the repair-and-replace paradigm,” said Francesco Maisano, MD, first user of the Cardioband procedure and chairman and a professor of cardiovascular surgery at The University Hospital of Zurich (Switzerland). “MR repair with Cardioband can be the first-line therapy for severe MR patients. Additionally, early-stage repair can support ventricular reverse remodeling while keeping the options open for the patient, supporting the technology's use at earlier stages.”

FMR is considered a disease of the left ventricle, not of the mitral valve, occurring when the left ventricle of the heart is distorted or enlarged, thus displacing the papillary muscles that support the two valve leaflets and stretching the annulus. Since the valve leaflets can no longer come together to close the annulus, blood flows back into the atrium. If left untreated, FMR overloads the heart and can lead to or accelerate heart failure.

Related Links:

Valtech Cardio



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.